BMO Capital has initiated coverage on Centessa Pharmaceuticals plc (NASDAQ:CNTA) with a price target of $19 (293% upside), and an Outperform rating. The…
BMO Capital analyst Kostas Biliouris initiates coverage on Centessa Pharmaceuticals (NASDAQ:CNTA) with a Outperform rating and announces Price Target of $19.
Centessa Pharmaceuticals plc (NASDAQ: CNTA), a clinical-stage pharmaceutical company with a Research & Development ("R&D") innovation engine that aims to discover, develop and ultimately deliver impactful medicines to patients, today announced presentation of the first preclinical data for LB101, PD-L1xCD47 LockBody, in a post